Resultados de la búsqueda - Portal de Modelos de Datos Médicos (MDM-Portal)

Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus Lab Panels NCT00529568

- 20/9/21 - 1 formulario, 6 itemgroups, 72 items, 1 idioma

Itemgroups: Chemistry, Haematology, Liver Chemistry Assessments, Renal Laboratory Parameters, Urinalysis Dipstick, Other Laboratory Screenings

The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR). NCT00529568 https://clinicaltrials.gov/ct2/show/NCT00529568 Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Treatment Official Title: Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2b Plus Ribavirin)

Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus Infection Lab panels NCT00996216

- 20/9/21 - 1 formulario, 6 itemgroups, 49 items, 1 idioma

Itemgroups: Clinical Chemistry, Haematology, Liver Chemistry, Renal Assessments, Urinalysis Dipstick, Other Laboratory Screenings

The purpose of this study is to test the safety and tolerability of eltrombopag when used to increase and maintain platelet count. Platelet count to be maintained at a level sufficient to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose reductions, and to avoid permanent discontinuation of antiviral therapy. NCT00996216 https://clinicaltrials.gov/ct2/show/NCT00996216 Study Type: Interventional Study Design: Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment Official Title: An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)

ADT and Gekid shared uniform oncological basic data set - Uniform oncological basic data set

- 20/9/21 - 1 formulario, 19 itemgroups, 123 items, 2 idiomas

Itemgroups: Reason for report, Administrative Data, Reporting institution, Diagnosis, Histology, TNM Classification, Other classifications, Residual status, Distant metastases, Surgery, Complications, Radiotherapy, Radiotherapy Side effects, Systemic therapy, Systemic or expectant treatment, Systemic therapy side effects, Follow-Up, Tumor conference, Death

The uniform oncological basic data set of ADT and GEKID was adopted in March 2008 and updated in February, 2014. It applies to all types of cancer and is continuously supplemented by tumor-specific modules. By harmonizing Oncology base record, an instrument has been created which provides a harmonized oncological standard , prevents multiple documentaries and allows comparable acquisition and evaluation of cancer treatments in all clinical structures and federal states . Source: http://www.tumorzentren.de/onkol-basisdatensatz.html

Framingham Risk Score

- 20/9/21 - 1 formulario, 1 itemgroup, 7 items, 1 idioma

Itemgroup: Score items

The Framingham Risk Score is a sex-specific algorithm used to estimate the 10-year cardiovascular risk of an individual. The Framingham Risk Score was first developed based on data obtained from the Framingham Heart Study, to estimate the 10-year risk of developing coronary heart disease. In order to assess the 10-year cardiovascular disease risk, cerebrovascular events, peripheral artery disease and heart failure were subsequently added as disease outcomes for the 2008 Framingham Risk Score, on top of coronary heart disease. (http://en.wikipedia.org/wiki/Framingham_Risk_Score)

OPS Chapter 5 SURGERIES

- 20/9/21 - 1 formulario, 1 itemgroup, 1 item, 2 idiomas

Itemgroup: OPS 5

derived from: OPS - German Procedure Classification https://www.dimdi.de/static/en/klassi/ops/index.htm DIMDI publishes the OPS classification on behalf of the Federal Ministry of Health; it is in the public domain. Its use in inpatient care is laid down in 301 Volume V of the German Social Security Code (SGB V) and for surgical procedures in the outpatient sector in 295 SGB V.

Clinical Data epSOS Patient summary

- 20/9/21 - 1 formulario, 15 itemgroups, 54 items, 3 idiomas

Itemgroups: Allergy, Medical Alert Information, History of Past Illness, Social History, Pregnancy History, Vaccination, Medical Devices and Implants, Medical problems (current), Vital Signs Observations, Diagnostic Tests, Disability or function, Medication, Surgical Procedure, Treatments, Care plan

derived from http://www.epsos.eu/ and http://decor.nictiz.nl/art-decor/decor-datasets--epsos-

ACCF/AHA 2011 Key Data Elements and Definitions of a Base Cardiovascular Vocabulary for Electronic Health Records - Key Data Elements

- 25/6/21 - 1 formulario, 11 itemgroups, 110 items, 2 idiomas

Itemgroups: History and Physical Examination Elements, Patient History, Family History, Patient Assessment, Laboratory Results Elements, Diagnostic and Therapeutic Procedures Elements, Diagnostic Procedure Results, Therapeutic Procedures, Therapeutic Procedure Device Implants, Pharmacological Therapy Data Elements, Outcomes Data Elements

http://circ.ahajournals.org/content/124/1/103.full

NCI Standard Adverse Event/Serious Adverse Event CTCAE v3 Template - 2748814v1.0 - NCI Standard Adverse Event/Serious Adverse Event CTCAE v3 Template

- 13/4/21 - 1 formulario, 4 itemgroups, 28 items, 1 idioma

Itemgroups: Mandatory Adverse Event Questions, Conditional Adverse Event Questions, Optional Adverse Event Questions, Optional Serious Adverse Event Questions

The collection of CDEs used in the Adverse Events/Serious Adverse Events module. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4D0BC7DD-57DD-63BE-E044-0003BA3F9857